Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Maxcyte (MXCT) EBITDA Margin (2020 - 2025)

Maxcyte (MXCT) has disclosed EBITDA Margin for 6 consecutive years, with 678.42% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 103239.0% to 678.42% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 29.45% through Dec 2025, down 1308.0% year-over-year, with the annual reading at 24.26% for FY2025, 1321.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 678.42% at Maxcyte, down from 191.71% in the prior quarter.
  • The five-year high for EBITDA Margin was 353.96% in Q4 2024, with the low at 678.42% in Q4 2025.
  • Average EBITDA Margin over 5 years is 161.89%, with a median of 147.45% recorded in 2021.
  • The sharpest move saw EBITDA Margin skyrocketed 88023bps in 2024, then tumbled -103239bps in 2025.
  • Over 5 years, EBITDA Margin stood at 425.03% in 2021, then soared by 93bps to 29.01% in 2022, then plummeted by -1714bps to 526.27% in 2023, then skyrocketed by 167bps to 353.96% in 2024, then tumbled by -292bps to 678.42% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 678.42%, 191.71%, and 154.44% for Q4 2025, Q3 2025, and Q2 2025 respectively.